Biomedical subjects

M Baldacci

Publications and source records attributed to M Baldacci.

7 recordsLinked to original sources

PubMed1990

"In vitro" fibrinolytic activity of a new low molecular weight heparan sulfate.

The fibrinolytic activity, effect on the fibrinolytic activity of plasmin, anticoagulant activity and anti platelet aggregation activity of a low molecular weight heparan sulfate (LMW HS Bal) were investigated "in vitro" on blood plasma obtained from rats and rabbits. LMW HS Bal at concentrations as low as 0.25-2 micrograms/ml prevented thrombin-induced platelet aggregation. At concentrations 25 to 50 times larger it showed no significant anticoagulant activity but a marked fibrinolytic effect. At still larger concentrations LMW HS Bal also potentiated the fibrinolytic activity of plasmin. Conversely, unfractionated heparan sulfate (UHS) at concentrations of 25 to 50 micrograms/ml, only showed anticoagulant activity with no fibrinolytic activity.

Animals↗

PubMed1990

Molecular design, synthesis, and antiinflammatory activity of a series of beta-aminoxypropionic acids.

Previous experimental and theoretical studies carried out on the mechanism of action of adrenergic drugs have shown that the (methyleneaminoxy)methyl moiety (C = NOCH2, MAOMM) can be considered as a "bioisostere" of an aryl group (Ar). On this basis, a series of substituted beta-aminoxypropionic acids (AOPAs) were synthesized as analogues of antiinflammatory arylacetic acids (ArAAs), in which the Ar portion is substituted by the MAOMM, with the aim of evaluating whether any antiinflammatory activity could be obtained from this class of drugs after the substitution of the Ar with the MAOMM. The antiinflammatory activity of the AOPAs synthesized was determined by carageenan-induced rat paw edema, using diclofenac as the reference drug. The pharmacological data showed that most of the AOPAs examined exhibit a significant antiinflammatory activity, which in the case of the (E)-3-(benzylideneaminoxy)propionic acid (7q) is very close to that of the reference drug. Structural and theoretical studies were carried out in order to compare the conformation and the molecular reactivity of the AOPAs with those of the ArAAs. Pharmacological results showed that the ArAAs also generally exhibit an antiinflammatory activity after the substitution of the Ar with the MAOMM, thus supporting the hypothesis of a bioisosterelike relationship between these two moieties in this class of NSAIDs.

Alanine↗

PubMed1989

On the effects of tranexamic acid and its isobenzedrine ester on plasminogen activation and streptokinase induced fibrinolysis.

A comparison between the inhibitory capability of Tranexamic acid (AMCA) and its isobenzedrine ester (IB-AMCA) on the streptokinase and urokinase induced plasminogen activation, indicated in vitro a higher potency of the ester derivative. A peculiar activatory rather than inhibitory effect on the plasminogen activation was exerted by AMCA and aminocaproic acid at relatively low concentrations. Attempts to show in vivo the in vitro observed differences between AMCA and IB-AMCA action are reported.

Animals↗

PubMed1988

Polypeptide fraction from bovine factor VIII does not influence human platelet aggregation and blood coagulation.

It is well known that high molecular weight bovine factor VIII is able to aggregate human platelets and possesses procoagulant activities. There is also growing body of evidence that the hydrolysis of bovine factor VIII abolishes its aggregating and coagulative properties. We have shown in this paper that a polypeptide fraction (molecular weight 1000-25000 daltons) from bovine factor VIII does not aggregate platelets nor affect blood coagulation. In this study we investigate the action of the polypeptide fraction derived from bovine factor VIII and suggest that its effect may occur only at endothelium level without an involvement of platelets as well as blood coagulation.

Animals↗

PubMed1988

Polypeptide fraction from bovine factor VIII used in fluorangiography.

We report a new method of fluorangiography employing a polypeptide fraction from bovine factor VIII that has shown remarkable affinity to the endothelial surface of microvessels. Rabbits injected with this compound, labeled with fluorescein isothiocyanate, show a very delayed disappearance time of fluorescence in retinal vessels when compared with those injected with ordinary fluorescein. This allows a good observation of the late time, which is of great diagnostic advantage for several pathological conditions.

Animals↗

PubMed1988

Decrease of bleeding time by a peptide fraction from bovine factor VIII in laboratory animals.

A peptide fraction of low molecular weight prepared from bovine Factor VIII by enzymatic hydrolysis (Vueffe) reduces bleeding time in laboratory animals. In this study the haemostatic action in mice, rats and rabbits was investigated using different experimental conditions. This action was observed in animals with either normal or experimentally prolonged bleeding time, thus suggesting better efficacy in pathological situations. The evidence obtained following different routes of administration confirmed the activity of the compound. The efficacy was present at very low doses in all animal species without interfering either with platelets or with blood coagulation.

Animals↗

PubMed1985

Effects of the "vascular factor" on platelet and vascular arachidonic acid metabolism in man.

The effects of a drug with hemostatic action, "Vascular Factor" (V.F.), on platelet and vascular arachidonic acid metabolism were evaluated in man to establish the lack of side effects on platelet aggregation. Plasma levels of 6-keto PGF1 alpha and thromboxane B2 were determined by RIA in healthy volunteers undergoing treatment with V.F. Results indicate that basal values obtained in these compounds do not present significant variations following treatment with V.F. On the basis of these results, the possibility of administering this drug in atherosclerotic patients is further confirmed.

6-Ketoprostaglandin F1 alpha↗